Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AbD Serotec, the research and diagnostic antibody unit of MorphoSys, has made changes in its existing licensing pact with Merck.
Subscribe to our email newsletter
Under the amended terms, AbD Serotec has given license to MorphoSys’ HuCAL GOLD technology to Merck for vaccine research.
The deal also allows Merck with an option to upgrade to MorphoSys’s latest proprietary antibody library HuCAL Platinum.
As per the terms of the agreement, Merck is responsible to pay annual user fees to AbD Serotec for accessing HuCAL technology.
Additionally, AbD Serotec will also receive license fees for clinical monitoring reagents from Merck.
Further financial details were not disclosed.